Axsome Therapeutics (AXSM) Expected to Announce Earnings on Tuesday

Axsome Therapeutics (NASDAQ:AXSM) is expected to release its earnings data before the market opens on Tuesday, February 18th. Analysts expect Axsome Therapeutics to post earnings of ($0.97) per share and revenue of $117.83 million for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Axsome Therapeutics Trading Down 0.4 %

NASDAQ:AXSM opened at $131.15 on Friday. The company has a quick ratio of 2.37, a current ratio of 2.44 and a debt-to-equity ratio of 1.97. Axsome Therapeutics has a 1-year low of $64.11 and a 1-year high of $134.18. The firm has a market capitalization of $6.36 billion, a price-to-earnings ratio of -20.08 and a beta of 1.05. The stock has a fifty day simple moving average of $97.84 and a 200 day simple moving average of $93.32.

Insider Transactions at Axsome Therapeutics

In related news, CFO Nick Pizzie sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $131.07, for a total value of $393,210.00. Following the transaction, the chief financial officer now directly owns 42,187 shares of the company’s stock, valued at approximately $5,529,450.09. This trade represents a 6.64 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 22.40% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on AXSM. Leerink Partners increased their price target on Axsome Therapeutics from $110.00 to $150.00 and gave the company an “outperform” rating in a research report on Monday, February 10th. Needham & Company LLC reiterated a “buy” rating and issued a $133.00 price target on shares of Axsome Therapeutics in a research report on Monday, February 10th. HC Wainwright restated a “buy” rating and set a $190.00 price objective on shares of Axsome Therapeutics in a research report on Tuesday, February 11th. Wells Fargo & Company raised their price objective on Axsome Therapeutics from $140.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $121.00 price objective on shares of Axsome Therapeutics in a research report on Thursday, December 12th. One research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat, Axsome Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $147.13.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.